New Delhi, Apr 22 (UNI) Drugs and chemicals maker Jubilant Organosys Ltd today said its net profit stood at Rs 41.1 crore for the fourth quarter ended March 31, 2008.
The revenues of the company has increased 48.7 per cent to Rs 689 crore over Q4 FY 2007. The international revenue was also higher by 107.4 per cent at Rs 442.9 crore for Q4FY08.
The consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) in Q4 stood at Rs 106.4 crore, however, the EBITDA before exchange loss and interest income on unused FCCB, has grown by 210.7 per cent to Rs 127.7 crore.
The Earnings Per Share (EPS) for Q4 FY08 was Rs 3.22.
The consolidated annual revenues increased by 37.5 per cent to Rs 2488.9 crore as compared to FY07.
The consolidated annual international revenue increased by 67.6 per cent to Rs 1394 crore. EBITDA over financial year grew by 59.5 per cent to Rs 606.7 crore, however, the EBITDA before exchange gain and interest income, has grown by 75.5 per cent to Rs 477.4 crore, while the net profit increased by 75.7 per cent to Rs 400.5 crore.
EPS grew by 72.2 per cent to Rs 22.42, the company said in a statement.
The Board of Directors of the company recommended the dividend of 150 per cent (previous year it was 125 per cent) on fully paid up equity shares of Re 1 each, for the year ended 31 March, 2008. This will result in a dividend payout of Rs 25.66 crore (including dividend tax).
The consolidated revenues from international operations stood at Rs 1394 crore, a 67.6 per cent growth on account of volume growth in the CRAMS business and addition of Hollister.
The revenue from North America and EU contributed 41.8 per cent and 25 per cent with a growth of 140per cent and 17 per cent respectively.
The company continues to see strong traction across existing businesses and expects over 35 per cent increase in revenue (without accounting for proposed acquisition of Draxis, the statement added.
UNI BJR AK HS1646